4:3 intermittent fasting is a structured dietary approach involving significant calorie restriction on three non-consecutive days each week, whilst eating normally on the remaining four days. Closely related to the popular 5:2 diet, it works by creating a sustained calorie deficit and triggering metabolic changes that may support weight management and cardiometabolic health. This article explains how 4:3 fasting works, what the current evidence says about its benefits, who should avoid it, how to follow it safely in the UK, and what NHS and NICE guidance says about intermittent fasting for weight management.

What Is 4:3 Intermittent Fasting and How Does It Work?

4:3 intermittent fasting restricts calories to around 25% of daily energy needs on three non-consecutive days per week, promoting fat utilisation through metabolic switching and improving insulin sensitivity on the remaining four normal eating days.

4:3 intermittent fasting is a structured dietary approach in which a person significantly restricts calorie intake on three non-consecutive days each week, whilst eating normally — though not excessively — on the remaining four days. It is closely related to alternate-day fasting and can be thought of as an extension of the well-known 5:2 diet, with one additional fasting day per week.

On fasting days, intake is typically limited to around 25% of an individual's estimated daily energy needs. As a rough guide, this equates to approximately 500 kcal for many women and 600 kcal for many men, though these figures are illustrative rather than fixed targets; actual requirements vary according to body size, age, and activity level. A registered dietitian can help calculate a more personalised fasting-day allowance.

The physiological basis of this approach centres on metabolic switching. During prolonged calorie restriction, the body depletes its glycogen stores and begins to utilise stored fat as an alternative energy source through lipolysis and, subsequently, ketogenesis. This metabolic shift is thought to underpin many of the proposed benefits associated with intermittent fasting regimens.

Unlike continuous calorie restriction, the 4:3 model allows for greater dietary flexibility on non-fasting days, which some individuals find psychologically easier to sustain over the long term. The pattern also influences hormonal regulation — notably reducing circulating insulin levels and improving insulin sensitivity, which may support blood glucose control. Some research in humans suggests that levels of human growth hormone may rise during fasting periods, though the clinical significance of this for fat metabolism and lean muscle preservation in everyday practice remains uncertain and should not be overstated.

It is important to note that 4:3 fasting is not a medically prescribed treatment but rather a lifestyle-based dietary strategy. Its effects vary considerably between people, and it is not universally suitable. Consulting a GP or registered dietitian before starting is strongly advisable, particularly for those with pre-existing health conditions or those taking regular medication.

Potential Health Benefits Supported by Current Evidence

Evidence supports modest, clinically meaningful weight loss and improvements in cardiometabolic markers such as fasting blood glucose, lipid profiles, and blood pressure, though benefits are largely attributable to the sustained calorie deficit rather than fasting timing itself.

Research into intermittent fasting, including variants such as 4:3, has grown considerably over the past decade. Several studies suggest that this approach can be an effective method for achieving modest but clinically meaningful weight loss. A well-cited randomised controlled trial by Trepanowski et al. (JAMA Internal Medicine, 2017) compared alternate-day fasting — closely related to 4:3 — with daily calorie restriction over 12 months and found broadly comparable weight loss between the two approaches, though adherence to alternate-day fasting was somewhat lower. More recent systematic reviews and meta-analyses (including those published in Obesity Reviews and Annual Review of Nutrition) broadly confirm that intermittent fasting and continuous energy restriction produce similar weight and cardiometabolic outcomes when overall calorie deficits are matched. It is important to note that the benefits observed are largely attributable to the sustained calorie deficit and improved diet quality achieved, rather than to the timing of eating per se.

Beyond weight management, intermittent fasting has been associated with improvements in several cardiometabolic markers, including:

• Reduced fasting blood glucose and insulin levels, which may improve risk factors associated with type 2 diabetes — though long-term outcome data in humans are limited and these findings should not be interpreted as evidence that fasting prevents or treats diabetes

• Modest improvements in lipid profiles, including reductions in LDL cholesterol and triglycerides, though effect sizes are generally small and variable

• Modest reductions in blood pressure, particularly in individuals who are overweight or obese

• Reduction in inflammatory markers such as C-reactive protein (CRP), though findings are inconsistent across studies

Some emerging research also points to potential benefits for cellular repair processes, including autophagy — the body's mechanism for clearing damaged cells — and for cognitive function. However, much of this evidence comes from animal studies or small, short-term human trials, and robust long-term data in humans remains limited. These areas should be regarded as speculative at present.

It is essential to interpret these findings with appropriate caution. The quality of evidence varies, many studies have small sample sizes or short follow-up periods, and benefits observed in research settings may not always translate directly to real-world outcomes. Current evidence supports 4:3 fasting as a reasonable option for weight management in otherwise healthy adults, but it should not be viewed as a treatment for any specific medical condition without professional guidance. The NHS and the British Dietetic Association (BDA) present intermittent fasting as one of several recognised approaches to weight management, without recommending it above other methods.

Who Should Avoid 4:3 Fasting or Seek Medical Advice First

Pregnant women, children, those with eating disorders, people with type 1 diabetes, and those taking insulin, sulfonylureas, or SGLT2 inhibitors should avoid 4:3 fasting without medical supervision due to significant safety risks.

Whilst 4:3 intermittent fasting may be appropriate for many healthy adults, it is not suitable for everyone. Certain groups should either avoid this dietary pattern entirely or seek medical advice before attempting it. Safety must always take precedence over any potential benefit.

Groups who should avoid 4:3 fasting without medical supervision include:

• Pregnant or breastfeeding women — calorie restriction during these periods can compromise maternal and infant nutrition

• Children and adolescents — growing bodies require consistent nutritional intake and should not undergo structured fasting regimens

• Individuals with a current or past history of eating disorders — restrictive eating patterns may trigger or exacerbate disordered eating behaviours; support is available from Beat, the UK's eating disorder charity (beateatingdisorders.org.uk)

• People with type 1 diabetes or those taking insulin or sulfonylureas — fasting significantly alters blood glucose dynamics and can increase the risk of hypoglycaemia

• People taking SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin, canagliflozin) — fasting and low-carbohydrate intake can increase the risk of euglycaemic diabetic ketoacidosis (DKA), a serious condition that may occur even when blood glucose appears normal; the MHRA has issued specific safety guidance on this risk

• Those with a BMI below 18.5 kg/m² (underweight) — further calorie restriction is inappropriate and potentially harmful

Individuals with type 2 diabetes managed by diet alone or with metformin may be able to undertake intermittent fasting, but should do so only under the supervision of their GP or diabetes care team, as medication adjustments may be necessary. Those taking GLP-1 receptor agonists (e.g., semaglutide, liraglutide) or orlistat should also seek medical advice, as fasting may interact with the gastrointestinal effects of these medicines or require dose review.

Additionally, people with chronic kidney disease, liver conditions, a history of cardiac arrhythmias, gout (fasting and rapid weight loss can precipitate gout flares), or those taking medicines for blood pressure or fluid balance should consult their GP before making significant dietary changes. Older adults should exercise particular caution, as fasting may increase the risk of muscle loss (sarcopenia), malnutrition, and nutritional deficiencies; a malnutrition risk assessment using a validated tool such as MUST (Malnutrition Universal Screening Tool) may be appropriate. A GP or registered dietitian can help assess individual suitability and tailor advice accordingly.

How to Follow a 4:3 Fasting Plan Safely in the UK

Schedule fasting days non-consecutively, prioritise high-protein and high-fibre foods within the calorie allowance, stay well hydrated, and align non-fasting days with the NHS Eatwell Guide to avoid negating the calorie deficit.

For those who have confirmed that 4:3 fasting is appropriate for them, following a structured and sensible approach is key to both safety and sustainability. The three fasting days should ideally be non-consecutive — for example, Monday, Wednesday, and Friday — to allow the body adequate recovery time and to prevent cumulative fatigue or nutritional depletion.

On fasting days (approximately 25% of individual daily energy needs; roughly 500–600 kcal as a guide for many adults):

• Prioritise high-protein, high-fibre foods to promote satiety — for example, eggs, grilled fish, lentils, vegetables, and low-fat dairy

• Spread calories across two small meals rather than one, if this helps manage hunger

• Stay well hydrated with water, herbal teas, or black coffee or tea (without milk or sugar) — these contain negligible calories and can help manage appetite

• Avoid high-sugar or highly processed foods, which provide little nutritional value within a restricted calorie allowance

• Avoid alcohol on fasting days, as it adds calories, increases dehydration, and can impair judgement around food choices

• Do not fast if you are acutely unwell, significantly dehydrated, or facing a day of intensive physical work or long-distance driving; if you feel unwell during a fast, eat something and seek advice if symptoms persist

On non-fasting days:

• Eat balanced, nutritious meals in line with the NHS Eatwell Guide, which recommends plenty of fruit, vegetables, wholegrains, lean proteins, and healthy fats

• Avoid the temptation to significantly overeat, as this can negate the calorie deficit achieved on fasting days

Regarding exercise, light to moderate activity is generally well tolerated on fasting days, but high-intensity exercise is best scheduled on non-fasting days, particularly during the initial adaptation period. If you feel dizzy or unwell during exercise on a fasting day, stop, eat something, and rest.

Planning meals in advance can be particularly helpful on fasting days. Using a calorie-tracking app or consulting a registered dietitian can support accurate portion control. It is also advisable to schedule fasting days around work and social commitments to minimise disruption. Regular monitoring of weight and wellbeing, ideally with professional support, helps ensure the approach remains safe and effective over time. The NHS Better Health programme and the BDA offer practical UK-based resources on healthy eating and weight management.

Common Side Effects and How to Manage Them

Most side effects — including hunger, headaches, and fatigue — are mild and resolve within two to four weeks; red flag symptoms such as chest pain, fainting, or signs of hypoglycaemia require prompt medical attention.

As with any significant change to dietary habits, 4:3 intermittent fasting can cause a range of side effects, particularly during the initial adjustment period. Most are mild and transient, resolving within the first two to four weeks as the body adapts to the new eating pattern.

Commonly reported side effects include:

• Hunger and irritability — often most pronounced in the first week; eating high-fibre and high-protein foods on fasting days can help

• Headaches — frequently related to dehydration or caffeine withdrawal; maintaining adequate fluid intake is important

• Fatigue and low energy — particularly on fasting days; scheduling rest and avoiding strenuous exercise on these days is advisable initially

• Difficulty concentrating — some individuals report brain fog on fasting days, though this often improves with adaptation

• Dizziness or light-headedness — may indicate dehydration or low blood pressure; sitting or lying down and drinking water usually resolves this; those taking antihypertensive or diuretic medicines should seek a medication review if this occurs regularly

• Constipation — can occur if fibre and fluid intake are insufficient; increasing vegetable consumption and hydration helps

• Gout flares — fasting and rapid weight loss can raise uric acid levels and trigger gout in susceptible individuals; seek medical advice if joint pain develops

• Gallstone symptoms — rapid weight loss is a recognised risk factor for gallstone formation; symptoms include pain in the upper right abdomen, nausea, and, in more serious cases, jaundice; seek prompt medical attention if these occur

If side effects are severe, persistent, or worsening, stop fasting and seek advice from a GP. Red flag symptoms that warrant prompt medical attention include: chest pain, palpitations, fainting, severe or persistent abdominal pain, persistent vomiting, black or tarry stools, jaundice, or signs of hypoglycaemia (shakiness, sweating, confusion) in those with diabetes or on glucose-lowering medicines.

Whilst serious adverse events appear uncommon in otherwise healthy adults following a sensible fasting regimen, individual responses vary and the risk is higher in those with underlying health conditions or on certain medications. Ongoing self-monitoring is an important part of practising any fasting regimen responsibly. If you suspect that a side effect may be related to a medicine or medical device, you can report this to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

NHS and NICE Guidance on Intermittent Fasting for Weight Management

NICE does not specifically endorse 4:3 fasting as a first-line obesity treatment, instead recommending a multicomponent approach; intermittent fasting is recognised by the NHS as one of several valid weight management options.

In the UK, the primary clinical framework for weight management is provided by NICE guideline CG189 (Obesity: identification, assessment and management) and NICE guideline PH53 (Weight management: lifestyle services for overweight or obese adults). Readers should note that NICE guidelines are periodically updated, and the most current versions should be consulted via the NICE website (nice.org.uk).

As of current guidance, NICE does not specifically endorse intermittent fasting — including 4:3 — as a first-line treatment for obesity or overweight. Instead, NICE recommends a multicomponent approach to weight management that includes dietary modification, increased physical activity, and behavioural support, delivered within a structured programme where possible. NICE CG189 emphasises that no single dietary approach is superior for all individuals, and that the most effective diet is one that a person can adhere to consistently over time whilst meeting their nutritional needs. In this context, intermittent fasting may be a valid option for some individuals, provided it is nutritionally adequate and medically appropriate.

The NHS website similarly presents intermittent fasting, including the 5:2 diet, as one of several recognised approaches to weight loss, without formally recommending it above other methods. The NHS Better Health programme provides practical, patient-facing resources on weight management and healthy eating.

For individuals with obesity-related conditions such as type 2 diabetes or hypertension, NICE guidance emphasises the importance of structured support from healthcare professionals, including GPs, practice nurses, and dietitians. Those seeking to use 4:3 fasting as part of a weight management strategy should ideally do so within this framework of professional oversight.

The MHRA and EMA do not regulate dietary approaches such as intermittent fasting, as these are lifestyle interventions rather than medicinal products. Nonetheless, patient safety remains paramount. Anyone using 4:3 fasting alongside prescribed medications — particularly those affecting blood glucose (including insulin, sulfonylureas, and SGLT2 inhibitors), blood pressure, or fluid balance — should inform their GP, as dosage adjustments may be required. Open communication with healthcare providers ensures that dietary changes complement, rather than conflict with, any ongoing medical management. If you believe a medicine or medical device has caused an adverse effect, please report it via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Frequently Asked Questions